104results about How to "Binding block" patented technology

The invention belongs to the field of oncotherapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and application of the PDL-1 antibody, in particular to a monoclonal antibody of PDL-1 or an antigen binding fragment thereof. A variable region of the heavy chain of the monoclonal antibody comprises CDR of which the amino acid sequence is SEQ ID NO: 15-17; and a variable region of the light chain of the monoclonal antibody comprises CDR of which the amino acid sequence is SEQ ID NO: 18-20. The monoclonal antibody can be well combined to PDL-1 specifically, inhibition of PDL-1 to body immunity is relieved specifically, and T lymphocyte is activated.

The invention relates to the technical field of medical biology, and specifically discloses a novel coronavirus (SARS-COV-2) spike protein binding molecule and applications thereof. The binding molecule can specifically bind the spike protein of SARS-COV-2 and includes at least one immunoglobulin single variable structural domain. The provided binding molecule can specifically bind the SARS-COV-2-Spike protein and effectively block the binding of the SARS-COV-2-Spike protein and human cell ACE2 receptors, so that the infection process of the SARS-COV-2 on cells can be further blocked, and theinfection and amplification of the SARS-COV-2 can be inhibited.

The invention belongs to the field of oncotherapy and molecular immunology, and relates to an anti-PD-L1 antibody as well as a pharmaceutical composition and an application of the anti-PD-L1 antibody. Particularly, the invention relates to a monoclonal antibody or an antigen binding fragment of the monoclonal antibody, wherein a heavy chain variable region of the monoclonal antibody comprises a CDR, the amino acid sequence of the CDR is SEQ ID NO:1-3, and/or a light chain variable region of the monoclonal antibody comprises a CDR, and the amino acid sequence of the CDR is SEQ ID NO:4-6. The monoclonal antibody is specifically bound with PD-L1 well, specifically relieves immunosuppression of PD-1 on the organism, and activates the T iymphocyte.

The invention discloses an anti-human PD-L1 antibody with high affinity, high specificity and multiple antigen recognition epitopes and having higher functionality. The PD-L1 monoclonal antibody can be specifically combined with PD-1, and can effectively block combination of PD-L1 and PD-1 protein, specifically relieve immune negative regulation of PD-L1, and activate T cell secretory cell factors. All the functions can reach a currently unique level of PD-L1 targeted drug Tecentriq (MPDL3280A), and partial antibodies have greater diversity by being different from epitope of Tecentriq. One PD-L1 antibody can promote combination of PD-L1 with PD-1 protein, but can still relieve immune negative regulation of PD-L1, and activate T cell secretory cell factors.

The invention discloses a monoclonal antibody of anti-human PIGF (placental growth factor) protein, which can be specifically bonded with human PIGF and block PIGF from joining receptors of the PIGF. The invention further discloses a preparation method of the monoclonal antibody. Besides, the invention discloses an application of the monoclonal antibody in qualitative and quantitative detection to the human PIGF protein. Furthermore, the invention discloses an application of the monoclonal antibody in preparing drugs for treating tumors.

The invention belongs to the field of tumor treatment and molecular immunology, and relates to an anti-VEGFA-anti-PD-1 bispecific antibody and an application thereof. Specifically, the anti-VEGFA-anti-PD-1 bispecific antibody comprises a PD-1-targeting first protein functional region and a VEGFA-targeting second protein functional region, according to an EU numbering system, a heavy chain constant region of immune globulin contained in the bispecific antibody mutates at two sites of 234 and 235, and after mutation, the affinity constant of the bispecific antibody is reduced compared to the affinity constant of Fc [gamma] RI, Fc [gamma] RIIa, Fc [gamma] RIIIa and/or C1q before mutation. The bispecific antibody disclosed by the invention can be specifically combined with VEGFA and PD-1, specifically relieve immunosuppression of VEGFA and PD-1 on an organism and inhibit angiogenesis caused by tumors at the same time, and has a good application prospect.

The invention discloses a group of PD-L1-resisting monoclonal antibodies and a medical application thereof and belongs to the field of oncotherapy and molecular immunology. The invention specificallyrelates to the group of PD-L1-resisting monoclonal antibodies and the medical application thereof. According to the invention, the group of PD-L1-resisting monoclonal antibodies, having an excellent effect of blocking the interaction between PD-L1 and PD-1, are obtained through a hybridoma technology. Humanized modification and affinity maturation are successfully performed on the antibodies. Theantibodies provided by the invention show a great application prospect of preparing medicines for blocking and adjusting the function and level of the PD-L1 and significantly enhancing organism immunity especially medicines for treating cancer.

The invention discloses a substitutive phenyl pyrimidine derivative as shown in a formula (I) as a JAK kinase inhibitor or medicinal salt, a preparation method and application thereof. The compound has excellent JAK inhibiting action and is used for preparing a drug for preventing, treating or improving autoimmune disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus and the like. The high activity JAK-3 inhibiting action IC50 shown by the compound can reach 1.7 n. The substitutive phenyl pyrimidine derivative is simple in synthetic route and high in implementation.

The invention provides a novel CD47 antibody or an immunocompetence fragment thereof, or a composition including the antibody/immunocompetence fragment. The CD47 antibody cannot cause red cell agglutination, and shows low combination at an extremely weak level or non-combination with red cells and blood platelets. The invention provides nucleic acid coding the CD47 antibody or the immunocompetencefragment, an expression vector and a host cell. In addition, the invention provides the purpose of the CD47 antibody or a medical composition containing the CD47 antibody/immunocompetence fragment for preparation of medicines for treating CD47 mediated diseases.

Polypeptides comprising monomer domains that bind to c-MET, or portions thereof, are provided.

The invention discloses single-stranded aptamer. A general formula of the single-stranded aptamer is 5'-AGAGACGGACACAGGATGAGC-NCCTTCCCCAAGACAGCATCCA-3', with N referring to a random sequence 35 to 45 bp in length; the single-stranded aptamer can specifically neutralize RhD antibody; N is SEQ ID NO.2, SEQ ID NO.7 or SEQ ID NO.8. The single-stranded aptamer can specifically neutralize the RhD antibody and can be made into a composition, a kit or a chip for detection of the RhD antibody; therapeutic agent made from the single-stranded aptamer is applicable to treatment of hemolytic disease of the newborn, and auxiliary made from the single-stranded aptamer is suitable for emergency blood transfusion of patients with negative RhD.

The invention provides an EGFR-CD3 bifunctional antibody. The bifunctional antibody comprises two same light chains and two same recombinant heavy chains, wherein the amino acid sequence of each lightchain is as shown in SEQ ID NO. 8, each recombinant heavy chain is formed by connecting an EGFR antibody heavy chain and a single-chain antibody scFv of CD3 protein through a linker sequence; the amino acid sequence of the EGFR antibody heavy chain is as shown in SEQ ID NO. 7; the amino acid sequence of the linker sequence linker is as shown in SEQ ID NO. 9; the amino acid sequence of the single-chain antibody scFv of the CD3 protein is shown as any one of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 or SEQ ID NO.6. The EGFR-CD3 bifunctional antibody can be specifically combined with human CD3 protein and EGFR, the immunogenicity of the murine antibody can be reduced, T cells can be effectively activated, the binding of human EGFR and EGFR can be blocked, the bifunctional antibody can be anchored on the surface of tumor cells by binding with EGFR, and can activate T cells by binding with CD3 so as to achieve the tumor cell killing purpose.

The invention discloses a human-mouse chimeric anti-CXCR2 full-molecule IgG and an application thereof and belongs to the field of biological pharmacy. The human-mouse chimeric anti-CXCR2 full-molecule IgG comprises a heavy chain variable region and a light chain variable region and is characterized in that the light chain variable region has a nucleic acid sequence shown in the formula of SEQ IDNO. 1 and the heavy chain variable region has a nucleic acid sequence shown in the formula of SEQ ID NO. 2. The mouse immunized by the specific recombinant CXCR2 protein is used, a mouse-derived anti-CXCR2 monoclonal antibody is prepared through a hybridoma technology, and the recombinant human-mouse chimeric anti-CXCR2 full-molecule IgG is prepared through genetic engineering and antibody engineering techniques. The chimeric antibody can effectively recognize the CXCR2 extracellular domain amino acid fragment and inhibit the binding of the CXCR2 protein to the GRO alpha protein.

The invention discloses an epitope-specific antibody screening method, and is used for solving the problem of low screening efficiency of functional antibodies having treatment function in an antibodylibrary screening technology; the method includes the steps of screening of functional epitope peptides and screening of living cells. The invention also provides a fully human anti-PD-1 monoclonal antibody obtained by screening a phage display antibody library by the method; for specific functional epitopes, the fully human anti-PD-1 monoclonal antibody can effectively block the binding of PD-1to a ligand of PD-1, has the characteristics of high affinity and low EC50, and can produce treatment effect on animal models at low dose. The screening efficiency of the functional antibody is greatly improved, and a potential, safer and more economical immunotherapy drug is provided for patients with malignant tumors and immune diseases.

The invention discloses development and an application of a therapeutic agent for TSLP-related diseases, and relates to an antibody binding to TSLP protein or an antigen binding part thereof as well as a preparation method and an application of the antibody. The antibody can be combined with human TSLP and/or cynomolgus monkey TSLP with high affinity, can block the combination of the TSLP and TSLPR, and can inhibit the transduction of a TSLP stimulating signal through an STAT5 pathway.

The invention relates to an anti-CD47 monoclonal antibody and use thereof. The anti-CD47 monoclonal antibody is secreted from a hybridoma cell strain with an accession number of CCTCC NO: C2018135.

The invention relates to the field of biological medicines, and particularly provides an injection preparation of an anti-IL-17RA monoclonal antibody. The preparation comprises pharmacodynamic molecules and a buffer solution, the pharmacodynamic molecules are the anti-IL-17RA monoclonal antibody, and the buffer solution comprises a buffer salt, a protein protective agent, an osmotic pressure regulator and a surfactant, wherein the pH value of the buffer solution is 5.5-6.5. According to the invention, all components in the buffer solution interact with each other for synergistic cooperation, astorage environment suitable for long-term storage is provided for the anti-IL-17RA monoclonal antibody, the degradation, aggregation or precipitation of the antibody caused in the long-term storageor transportation process of the preparation can be avoided, the antibody can be stored in the environment for 36 months or more, the activity and the purity of the antibody can be kept stable in thestorage period, and the drug effect of the biological drug is guaranteed; the injection preparation can be used for various autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis, ankylosing spondylitis or scleroderma and the like.

The invention discloses a closed IL6R CAR-T transgenic vector for relieving CRS. The vector consists of an amicillin resistance gene AmpR sequence (SEQ ID NO.1), a prokaryotic replicon pUC Ori sequence (SEQ ID NO.2), a virus replicon SV40 Ori sequence (SEQ ID NO.3), an eWPRE-enhanced marmot hepatitis B virus post-transcriptional regulatory element (SEQ ID NO.11), a human EF1[alpha] promoter (SEQ ID NO.12), a lentivirus packaging cis element applied to lentivirus packaging, a human IL6R humanized single-chain antibody IL6RscFv1 (SEQ ID NO.21) or IL6RscFv2 (SEQ ID NO.22) or IL6RscFv3 (SEQ ID NO.23), an IRES ribosome bonding sequence (SEQ ID NO.25), an IL6 signal peptide (SEQ ID NO.26), a humanized antibody Fc segment (SEQ ID NO.27) and a chimeric antigen receptor for constituting a second-generation or third-generation CAR integrating recognition, transferring and promoting. In addition, the invention also discloses a construction method of the vector and an application of the vector inpreparing medicines for relieving CRS.

The loss of the SOST gene product sclerostin leads to sclerosteosis characterized byihigh bone mass (HBM). In this report, we found that sclerostin could antagonize canonical, Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.

The invention provides a novel humanized neutralizing active monoclonal antibody against novel coronavirus and application thereof. The monoclonal antibody with neutralizing activity is separated andscreened from the body of a rehabilitation patient infected with the novel coronavirus, has excellent affinity and specificity for the novel coronavirus (SARS-CoV-2), and can effectively block the combination of the novel coronavirus and receptor protein.